Publications

1. Seyedi S, Harris VK, Kapsetaki SE, Narayanan S, Saha D, Compton Z, Yousefi R, May A, Fakir E, Boddy AM, Gerlinger M, Wu C, Mina L, Huijben S, Gouge DH, Cisneros L, Ellsworth PC, Maley CC. Resistance Management for Cancer: Lessons from Farmers. Cancer Res. 2024 Oct 2 Epub 2024 Oct 02
   View PubMed
2. Benson AB, Venook AP, Adam M, Chang G, Chen YJ, Ciombor KK, Cohen SA, Cooper HS, Deming D, Garrido-Laguna I, Grem JL, Haste P, Hecht JR, Hoffe S, Hunt S, Hussan H, Johung KL, Joseph N, Kirilcuk N, Krishnamurthi S, Malla M, Maratt JK, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Shogan B, Skibber JM, Sofocleous CT, Tavakkoli A, Willett CG, Wu C, Jones F, Gurski L. NCCN Guidelines(R) Insights: Rectal Cancer, Version 3.2024. J Natl Compr Canc Netw. 2024 Aug; 22 (6):366-375
   View PubMed
3. Eslinger C, Wu C, Ahn DH. Minimal residual disease monitoring via ctDNA: a case report of Lynch syndrome with synchronous colorectal cancer and review of literature. J Gastrointest Oncol. 2024 Jun 30; 15 (3):1341-1347 Epub 2024 June 19
   View PubMed
4. Benson AB, Venook AP, Adam M, Chang G, Chen YJ, Ciombor KK, Cohen SA, Cooper HS, Deming D, Garrido-Laguna I, Grem JL, Haste P, Hecht JR, Hoffe S, Hunt S, Hussan H, Johung KL, Joseph N, Kirilcuk N, Krishnamurthi S, Malla M, Maratt JK, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Shogan B, Skibber JM, Sofocleous CT, Tavakkoli A, Willett CG, Wu C, Gurski LA, Snedeker J, Jones F. Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024 Jun; 22 (2 D)
   View PubMed
5. Sinicrope FA, Nelson GD, Saberzadeh-Ardestani B, Segovia DI, Graham RP, Wu C, Hagen CE, Shivji S, Savage P, Buchanan DD, Jenkins MA, Phipps AI, Swallow C, LeMarchand L, Gallinger S, Grant RC, Pai RK, Sinicrope SN, Yan D, Shanmugam K, Conner J, Cyr DP, Kirsch R, Banerjee I, Alberts SR, Shi Q, Pai RK. Use of Deep Learning to Evaluate Tumor Microenvironmental Features for Prediction of Colon Cancer Recurrence. Cancer Res Commun. 2024 May 23; 4 (5):1344-1350
   View PubMed
6. Wu C, Pai RK, Kosiorek H, Banerjee I, Pfeiffer A, Hagen CE, Hartley CP, Graham RP, Sonbol MB, Bekaii-Saab T, Xie H, Sinicrope FA, Patel B, Westerling-Bui T, Shivji S, Conner J, Swallow C, Savage P, Cyr DP, Kirsch R, Pai RK. Improved Risk-Stratification Scheme for Mismatch-Repair Proficient Stage II Colorectal Cancers Using the Digital Pathology Biomarker QuantCRC. Clin Cancer Res. 2024 May 1; 30 (9):1811-1821
   View PubMed
7. Hitchcock KE, Miller ED, Shi Q, Dixon JG, Gholami S, White SB, Wu C, Goulet CC, George M, Jee KW, Wright CL, Yaeger R, Shergill A, Hong TS, George TJ, O'Reilly EM, Meyerhardt JA, Romesser PB. Alliance for clinical trials in Oncology (Alliance) trial A022101/NRG-GI009: a pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer: evaluating radiation, ablation, and surgery (ERASur). BMC Cancer. 2024 Feb 13; 24 (1):201
   View PubMed
8. Akce M, Farran B, Switchenko JM, Rupji M, Kang S, Khalil L, Ruggieri-Joyce A, Olson B, Shaib WL, Wu C, Alese OB, Diab M, Lesinski GB, El-Rayes BF. Phase II trial of nivolumab and metformin in patients with treatment-refractory microsatellite stable metastatic colorectal cancer. J Immunother Cancer. 2023 Oct; 11 (10)
   View PubMed
9. Elhariri A, Alhaj A, Ahn D, Sonbol MB, Bekaii-Saab T, Wu C, Rutenberg MS, Stauffer J, Starr J, Majeed U, Jones J, Borad M, Babiker H. Targeting KRAS in pancreatic adenocarcinoma: Progress in demystifying the holy grail. World J Clin Oncol. 2023 Aug 24; 14 (8):285-296
   View PubMed
10. Ou FS, Walden DJ, Larson JJ, Kang S, Griswold CR, Ueberroth BE, Patel B, Draper A, Raman P, Alese OB, Sonbol MB, Bekaii-Saab TS, Wu CS, Ahn DH. Changes in Prescribing Patterns in Stage III Colon Cancer. J Natl Compr Canc Netw. 2023 Aug; 21 (8):841-850.e4
    View PubMed
11. Strickler JH, Cercek A, Siena S, Andre T, Ng K, Van Cutsem E, Wu C, Paulson AS, Hubbard JM, Coveler AL, Fountzilas C, Kardosh A, Kasi PM, Lenz HJ, Ciombor KK, Elez E, Bajor DL, Cremolini C, Sanchez F, Stecher M, Feng W, Bekaii-Saab TS, MOUNTAINEER investigators. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. Lancet Oncol. 2023 May; 24 (5):496-508
    View PubMed
12. Alese OB, Wu C, Chapin WJ, Ulanja MB, Zheng-Lin B, Amankwah M, Eads J. Update on Emerging Therapies for Advanced Colorectal Cancer. Am Soc Clin Oncol Educ Book. 2023 May; 43:e389574.
    View PubMed
13. Mettu NB, Ou FS, Zemla TJ, Halfdanarson TR, Lenz HJ, Breakstone RA, Boland PM, Crysler OV, Wu C, Nixon AB, Bolch E, Niedzwiecki D, Elsing A, Hurwitz HI, Fakih MG, Bekaii-Saab T. Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA Netw Open. 2022 Feb 1; 5 (2):e2149040 Epub 2022 Feb 01
    View PubMed
14. Herting CJ, Farren MR, Tong Y, Liu Z, O'Neil B, Bekaii-Saab T, Noonan A, McQuinn C, Mace TA, Shaib W, Wu C, El-Rayes BF, Shahda S, Lesinski GB. A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN GI14-186. Cancer Immunol Immunother. 2021 Nov; 70 (11):3337-3348 Epub 2021 June 23
    View PubMed
15. Jones J, Ciombor K, Wu C, Bekaii-Saab T, Strickler J. Addressing Resistance to Targeted Therapies in Metastatic Colorectal Cancer. Oncology (Williston Park). 2021 Oct 21; 35 (10):654-660
    View PubMed
16. Ciombor K, Jones J, Strickler J, Bekaii-Saab T, Wu C. The Current Molecular Treatment Landscape of Advanced Colorectal Cancer and Need for the COLOMATE Platform. Oncology (Williston Park). 2021 Sep 15; 35 (9):553-559 Epub 2021 Sept 15
    View PubMed
17. Sahin IH, Goyal S, Pumpalova Y, Sonbol MB, Das S, Haraldsdottir S, Ahn D, Ciombor KK, Chen Z, Draper A, Berlin J, Bekaii-Saab T, Lesinski GB, El-Rayes BF, Wu C. Mismatch Repair (MMR) Gene Alteration and BRAF V600E Mutation Are Potential Predictive Biomarkers of Immune Checkpoint Inhibitors in MMR-Deficient Colorectal Cancer. Oncologist. 2021 Aug; 26 (8):668-675 Epub 2021 Mar 22
    View PubMed
18. Draper AS, Lafollette J, Kim C, Wu CS. Retrospective study evaluating the safety of administering pegfilgrastim on the final day of 5-fluorouracil continuous intravenous infusion. J Oncol Pharm Pract. 2021 Jul; 27 (5):1159-1164 Epub 2020 Aug 06
    View PubMed
19. Kang S, Wu C. Total Neoadjuvant Approach in Rectal Adenocarcinoma. Clinical Advances in Hematology and Oncology. 2021; 19.
    
20. Alese OB, Zhou W, Jiang R, Zakka K, Huang Z, Okoli C, Shaib WL, Akce M, Diab M, Wu C, El-Rayes BF. Predictive and Prognostic Effects of Primary Tumor Size on Colorectal Cancer Survival. Front Oncol. 2021; 11:728076 Epub 2021 Dec 09
    View PubMed
21. Harvey RD, Carthon BC, Lewis C, Hossain MS, Zhang C, Chen Z, Harris WB, Alese OB, Shaib W, Bilen MA, Lawson DH, Wu C, Steuer CE, El-Rayes BF, Khuri FR, Lonial S, Waller EK, Ramalingam SS, Owonikoko TK. Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma. Br J Cancer. 2020 Oct; 123 (8):1228-1234 Epub 2020 July 24
    View PubMed
22. Shaib WL, Zakka KM, Jiang R, Yan M, Alese OB, Akce M, Wu C, Behera M, El-Rayes BF. Survival outcome of adjuvant chemotherapy in deficient mismatch repair stage III colon cancer. Cancer. 2020 Sep 15; 126 (18):4136-4147 Epub 2020 July 22
    View PubMed
23. Hianik RS, Campbell GP, Abernethy E, Lewis C, Wu CS, Akce M, Dixon MD, Shaib WL, Pentz RD. Provider Recommendations for Phase I Clinical Trials Within a Shared Decision-Making Model in Phase I Cancer Clinical Trial Discussions. JCO Oncol Pract. 2020 Sep; 16 (9):e859-e867 Epub 2020 May 19
    View PubMed
24. Enofe N, Morris AD, Liu Y, Liang W, Wu CS, Sullivan PS, Balch GG, Staley CA, Gillespie TW, Shaffer VO. Receipt of Adjuvant Chemotherapy in Stage II Colon Cancer and Overall Survival: A National Cancer Database Study. J Surg Res. 2020 Aug; 252:69-79 Epub 2020 Mar 31
    View PubMed
25. Das S, Ciombor KK, Haraldsdottir S, Pumpalova Y, Sahin IH, Pineda G, Shyr Y, Lin EP, Hsu CY, Chu SK, Goff LW, Cardin DB, Bilen MA, Fisher GA, Wu C, Berlin J. Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy. Oncologist. 2020 Aug; 25 (8):669-679 Epub 2020 Jan 14
    View PubMed
26. Nagaraju GP, Farran B, Farren M, Chalikonda G, Wu C, Lesinski GB, El-Rayes BF. Napabucasin (BBI 608), a potent chemoradiosensitizer in rectal cancer. Cancer. 2020 Jul 15; 126(14):3360-3371. Epub 2020 May 08.
    View PubMed
27. Wu C, Williams TM, Robb R, Webb A, Wei L, Chen W, Mikhail S, Ciombor KK, Cardin DB, Timmers C, Krishna SG, Arnold M, Harzman A, Abdel-Misih S, Roychowdhury S, Bekaii-Saab T, Wuthrick E. Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer. Clin Cancer Res. 2020 Jul 1; 26 (13):3117-3125 Epub 2020 Apr 06
    View PubMed
28. Shaib WL, Zakka K, Shahin AA, Yared F, Switchenko JM, Wu C, Akce M, Alese OB, Patel PR, Mcdonald M, El-Rayes BF. Radiation as a Single-Modality Treatment in Localized Pancreatic Cancer. Pancreas. 2020 Jul; 49 (6):822-829
    View PubMed
29. Owonikoko TK, Harvey RD, Carthon B, Chen Z, Lewis C, Collins H, Zhang C, Lawson DH, Alese OB, Bilen MA, Sica GL, Steuer CE, Shaib WL, Wu C, Harris WB, Akce M, Kudchagkar RR, El-Rayes BF, Lonial S, Ramalingam SS, Khuri FR. A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors. Clin Cancer Res. 2020 Jun 1; 26 (11):2497-2505 Epub 2020 Jan 31
    View PubMed
30. Sahin IH, Kane SR, Brutcher E, Guadagno J, Smith KE, Wu C, Lesinski GB, Gunthel CJ, El-Rayes BF. Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer Living With HIV: A Perspective on Recent Progress and Future Needs. JCO Oncol Pract. 2020 Jun; 16 (6):319-325 Epub 2020 Mar 11
    View PubMed
31. Zakka K, Nagy R, Drusbosky L, Akce M, Wu C, Alese OB, El-Rayes BF, Kasi PM, Mody K, Starr J, Shaib WL. Blood-based next-generation sequencing analysis of neuroendocrine neoplasms. Oncotarget. 2020 May 12; 11 (19):1749-1757
    View PubMed
32. Shaib WL, Zakka K, Hoodbhoy FN, Belalcazar A, Kim S, Cardona K, Russell MC, Maithel SK, Sarmiento JM, Wu C, Akce M, Alese OB, El-Rayes BF. In-hospital 30-day mortality for older patients with pancreatic cancer undergoing pancreaticoduodenectomy. J Geriatr Oncol. 2020 May; 11 (4):660-667 Epub 2019 Nov 06
    View PubMed
33. Alese OB, Jiang R, Shaib W, Wu C, Akce M, Behera M, El-Rayes BF. High-Grade Gastrointestinal Neuroendocrine Carcinoma Management and Outcomes: A National Cancer Database Study. Oncologist. 2020 May; 25 (5):e877
    View PubMed
34. Shaib WL, Zakka K, Staley C 3rd, Roberts A, Akce M, Wu C, Alese OB, El-Rayes BF. Blood-Based Next-Generation Sequencing Analysis of Appendiceal Cancers. Oncologist. 2020 May; 25 (5):414-421 Epub 2019 Nov 29
    View PubMed
35. Bilen MA, Martini DJ, Liu Y, Shabto JM, Brown JT, Williams M, Khan AI, Speak A, Lewis C, Collins H, Kissick HT, Carthon BC, Akce M, Shaib WL, Alese OB, Pillai RN, Steuer CE, Wu CS, Lawson DH, Kudchadkar RR, El-Rayes BF, Ramalingam SS, Owonikoko TK, Harvey RD, Master VA. Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy. Oncologist. 2020 Mar; 25 (3):e528-e535 Epub 2019 Dec 05
    View PubMed
36. Alese OB, Jiang R, Shaib W, Wu C, Akce M, Gaines T, Ni L, Behera M, El-Rayes BF. Young Adults With Pancreatic Cancer: National Trends in Treatment and Outcomes. Pancreas. 2020 Mar; 49 (3):341-354
    View PubMed
37. Martini DJ, Kline MR, Liu Y, Shabto JM, Williams MA, Khan AI, Lewis C, Collins H, Akce M, Kissick HT, Carthon BC, Shaib WL, Alese OB, Pillai RN, Steuer CE, Wu CS, Lawson DH, Kudchadkar RR, El-Rayes BF, Ramalingam SS, Owonikoko TK, Harvey RD, Master VA, Bilen MA. Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials. Cancer. 2020 Feb 1; 126 (3):575-582 Epub 2019 Oct 24
    View PubMed
38. Duininck G, Lopez-Aguiar AG, Lee RM, Miller L, Dariushnia S, Wu C, Alese OB, Lin JY, Wedd J, Adams A, Maithel SK, Russell MC. Optimizing cancer care for hepatocellular carcinoma at a safety-net hospital: The value of a multidisciplinary disease management team. J Surg Oncol. 2019 Dec; 120 (8):1365-1370 Epub 2019 Oct 22
    View PubMed
39. Martini DJ, Liu Y, Shabto JM, Lewis C, Kline MR, Collins H, Akce M, Kissick HT, Carthon BC, Shaib WL, Alese OB, Pillai RN, Steuer CE, Wu CS, Lawson DH, Kudchadkar RR, Master VA, El-Rayes BF, Ramalingam SS, Owonikoko TK, Harvey RD, Bilen MA. Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials. Invest New Drugs. 2019 Dec; 37 (6):1198-1206 Epub 2019 Feb 06
    View PubMed
40. Akce M, Zakka K, Penley M, Jiang R, Alese OB, Shaib WL, Wu C, Behera M, El-Rayes BF. Clinicopathological features and survival outcomes of rare histologic variants of gallbladder cancer. J Surg Oncol. 2019 Nov 28 [Epub ahead of print]
    View PubMed
41. Bilen MA, Shabto JM, Martini DJ, Liu Y, Lewis C, Collins H, Akce M, Kissick H, Carthon BC, Shaib WL, Alese OB, Steuer CE, Wu C, Lawson DH, Kudchadkar R, Master VA, El-Rayes B, Ramalingam SS, Owonikoko TK, Harvey RD. Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy. BMC Cancer. 2019 Aug 29; 19 (1):857
    View PubMed
42. Shaib WL, Sayegh L, Zhang C, Belalcazar A, Ip A, Alese OB, Akce M, Wu C, Qu Y, Maithel SK, Kooby D, Cardona K, Sarmeinto JM, El-Rayes BF. Induction Therapy in Localized Pancreatic Cancer. Pancreas. 2019 Aug; 48 (7):913-919
    View PubMed
43. Alese OB, Jiang R, Shaib W, Wu C, Akce M, Behera M, El-Rayes BF. High-Grade Gastrointestinal Neuroendocrine Carcinoma Management and Outcomes: A National Cancer Database Study. Oncologist. 2019 Jul; 24 (7):911-920 Epub 2018 Nov 27
    View PubMed
44. Bekaii-Saab T, Wesolowski R, Ahn DH, Wu C, Mortazavi A, Lustberg M, Ramaswamy B, Fowler J, Wei L, Overholser J, Kaumaya PTP. Phase I Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines Emulsified in Montanide ISA 720VG and Nor-MDP Adjuvant in Patients with Advanced Solid Tumors. Clin Cancer Res. 2019 Jun 15; 25(12):3495-3507. Epub 2019 Feb 25.
    View PubMed
45. Akce M, Jiang R, Alese OB, Shaib WL, Wu C, Behera M, El-Rayes BF. Gastric squamous cell carcinoma and gastric adenosquamous carcinoma, clinical features and outcomes of rare clinical entities: a National Cancer Database (NCDB) analysis. J Gastrointest Oncol. 2019 Feb; 10 (1):85-94
    View PubMed
46. Akce M, Jiang R, Zakka K, Wu C, Alese OB, Shaib WL, Behera M, El-Rayes BF. Clinical outcomes of small bowel adenocarcinomas. Clinical Colorectal Cancer. 2019; S1533-0028(19):30286-5.
    
47. Alese OB, Jiang R, Zakka KM, Wu C, Shaib W, Akce M, Beheara M, El-Rayes BF. Analysis of racial disparities in the treatment and outcomes of colorectal cancer in young adults. Cancer Epidemiol. 2019; 63:101618.
    
48. Zakka K, Jiang R, Alese OB, Shaib WL, Wu C, Wedd JP, Sellers MT, Behera M, El-Rayes BF, Akce M. Clinical outcomes of rare hepatocellular carcinoma variants compared to pure hepatocellular carcinoma. J Hepatocell Carcinoma. 2019; 6:119-129 Epub 2019 July 22
    View PubMed
49. George TJ, Franke AJ, Chakravarthy AB, Das P, Dasari A, El-Rayes BF, Hong TS, Kinsella TJ, Landry JC, Lee JJ, Monjazeb AM, Raben D, Rahma OE, Williams TM, Wu C, Coleman N, Vikram B, Ahmed MM. NCI State of the Science: Targeted Radiosensitizers in Colorectal Cancer. Cancer. 2019; 125:2732-46.
    
50. Sahin I, Akce M. Alese OB, Shaib W, Lesinski GB, El-Rayes B, Wu C. Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms. British Journal of Cancer. 2019.
    
51. Shaib WL, Narayan AS, Switchenko JM, Kane SR, Wu C, Akce M, Alese OB, Patel PR, Maithel SK, Sarmiento JM, Kooby DA, El-Rayes BF. Role of adjuvant therapy in resected stage IA subcentimeter (T1a/T1b) pancreatic cancer. Cancer. 2019 Jan 1; 125 (1):57-67 Epub 2018 Nov 20
    View PubMed
52. Bilen MA, Martini DJ, Liu Y, Lewis C, Collins HH, Shabto JM, Akce M, Kissick HT, Carthon BC, Shaib WL, Alese OB, Pillai RN, Steuer CE, Wu CS, Lawson DH, Kudchadkar RR, El-Rayes BF, Master VA, Ramalingam SS, Owonikoko TK, Harvey RD. The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy. Cancer. 2019 Jan 1; 125 (1):127-134 Epub 2018 Oct 17
    View PubMed
53. Chu PC, Lin PC, Wu HY, Lin KT, Wu C, Bekaii-Saab T, Lin YJ, Lee CT, Lee JC, Chen CS. Mutant KRAS promotes liver metastasis of colorectal cancer, in part, by upregulating the MEK-Sp1-DNMT1-miR-137-YB-1-IGF-IR signaling pathway. Oncogene. 2018 Jun; 37 (25):3440-3455 Epub 2018 Mar 21
    View PubMed
54. Shaib WL, Jones JS, Goodman M, Sarmiento JM, Maithel SK, Cardona K, Kane S, Wu C, Alese OB, El-Rayes BF. Evaluation of Treatment Patterns and Survival Outcomes in Elderly Pancreatic Cancer Patients: A Surveillance, Epidemiology, and End Results-Medicare Analysis. Oncologist. 2018 Jun; 23 (6):704-711 Epub 2018 Feb 14
    View PubMed
55. Kim HS, Shaib WL, Zhang C, Nagaraju GP, Wu C, Alese OB, Chen Z, Brutcher E, Renfroe M, El-Rayes BF. Phase 1b study of pasireotide, everolimus, and selective internal radioembolization therapy for unresectable neuroendocrine tumors with hepatic metastases. Cancer. 2018 May 1; 124 (9):1992-2000 Epub 2018 Feb 16
    View PubMed
56. Ahn DH, Reardon J, Ahn CW, Bupathi M, Mikhail S, Wu CS, Bekaii-Saab T. Biweekly cisplatin and gemcitabine in patients with advanced biliary tract cancer. Int J Cancer. 2018 Apr 15; 142 (8):1671-1675 Epub 2017 Nov 17
    View PubMed
57. Nguyen P, Wuthrick E, Chablani P, Robinson A, Simmons L, Wu C, Arnold M, Harzman AE, Husain S, Schmidt C, Abdel-Misih S, Bekaii-Saab T, Chakravarti A, Williams TM. Does Delaying Surgical Resection After Neoadjuvant Chemoradiation Impact Clinical Outcomes in Locally Advanced Rectal Adenocarcinoma?: A Single-Institution Experience. Am J Clin Oncol. 2018 Feb; 41(2):140-146.
    View PubMed
58. Wu C, El-Rayes BF. A Patient-Centered Team Approach in Oncology. Cancer. 2018; 124:1856-8.
    
59. Wu C. Systemic Therapy for Colon Cancer. Surg Oncol Clin N Am. 2018; 27:235-42.
    
60. Ahn DH, Wu C, Wei L, Williams TM, Wuthrick E, Abdel-Misih S, Harzman A, Husain S, Schmidt C, Goldberg RM, Bekaii-Saab T. The Efficacy of Adjuvant Chemotherapy in Patients With Stage II/III Resected Rectal Cancer Treated With Neoadjuvant Chemoradiation Therapy. Am J Clin Oncol. 2017 Dec; 40(6):531-534.
    View PubMed
61. Chablani P, Nguyen P, Pan X, Robinson A, Walston S, Wu C, Frankel WL, Chen W, Bekaii-Saab T, Chakravarti A, Wuthrick E, Williams TM. Perineural Invasion Predicts for Distant Metastasis in Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiation and Surgery. Am J Clin Oncol. 2017 Dec; 40(6):561-568.
    View PubMed
62. Strickler JH, Wu C, Bekaii-Saab T. Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches. Cancer Treat Rev. 2017 Nov; 60:109-119 Epub 2017 Aug 31
    View PubMed
63. Nagaraju GP, Wu C, Merchant N, Chen Z, Lesinski GB, El-Rayes BF. Epigenetic effects of inhibition of heat shock protein 90 (HSP90) in human pancreatic and colon cancer. Cancer Lett. 2017 Aug 28; 402:110-116 Epub 2017 June 03
    View PubMed
64. Benson AB 3rd, Venook AP, Cederquist L, Chan E, Chen YJ, Cooper HS, Deming D, Engstrom PF, Enzinger PC, Fichera A, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wu CS, Gregory KM, Freedman-Cass D. Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 Mar; 15(3):370-398.
    View PubMed
65. Ahn DH, Krishna K, Blazer M, Reardon J, Wei L, Wu C, Ciombor KK, Noonan AM, Mikhail S, Bekaii-Saab T. A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis. Ther Adv Med Oncol. 2017 Feb; 9 (2):75-82 Epub 2016 Nov 02
    View PubMed
66. Ahn DH, Javle M, Ahn CW, Jain A, Mikhail S, Noonan AM, Ciombor K, Wu C, Shroff RT, Chen JL, Bekaii-Saab T. Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance. Cancer. 2016 Dec 1; 122 (23):3657-3666 Epub 2016 Aug 06
    View PubMed
67. Haraldsdottir S, Hampel H, Wu C, Weng DY, Shields PG, Frankel WL, Pan X, de la Chapelle A, Goldberg RM, Bekaii-Saab T. Patients with colorectal cancer associated with Lynch syndrome and MLH1 promoter hypermethylation have similar prognoses. Genet Med. 2016 Sep; 18(9):863-8. Epub 2016 Feb 11.
    View PubMed
68. Brathwaite S, Rock J, Yearsley MM, Bekaii-Saab T, Wei L, Frankel WL, Hays J, Wu C, Abdel-Misih S. Mixed Adeno-neuroendocrine Carcinoma: An Aggressive Clinical Entity. Ann Surg Oncol. 2016 Jul; 23(7):2281-6. Epub 2016 Mar 10.
    View PubMed
69. Noonan AM, Farren MR, Geyer SM, Huang Y, Tahiri S, Ahn D, Mikhail S, Ciombor KK, Pant S, Aparo S, Sexton J, Marshall JL, Mace TA, Wu CS, El-Rayes B, Timmers CD, Zwiebel J, Lesinski GB, Villalona-Calero MA, Bekaii-Saab TS. Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma. Mol Ther. 2016 Jun; 24 (6):1150-1158 Epub 2016 Apr 04
    View PubMed
70. Farren MR, Mace TA, Geyer S, Mikhail S, Wu C, Ciombor K, Tahiri S, Ahn D, Noonan AM, Villalona-Calero M, Bekaii-Saab T, Lesinski GB. Systemic Immune Activity Predicts Overall Survival in Treatment-Naïve Patients with Metastatic Pancreatic Cancer. Clin Cancer Res. 2016 May 15; 22(10):2565-74. Epub 2015 Dec 30.
    View PubMed
71. Bupathi M, Ahn DH, Wu C, Ciombor KK, Stephens JA, Reardon J, Goldstein DA, Bekaii-Saab T. Modified irinotecan and infusional 5-fluorouracil (mFOLFIRI) in patients with refractory advanced pancreas cancer (APC): a single-institution experience. Med Oncol. 2016 Apr; 33(4):37. Epub 2016 Mar 19.
    View PubMed
72. George TJ, Wu C, You YN. NRG G1002: Moving the needle toward TNT in locally advanced rectal cancer. Bul Am Coll Surg. 2016; 101:61-2.
    
73. Bupathi M, Wu C. Biomarkers for immune therapy in colorectal cancer: mismatch-repair deficiency and others. J Gastrointest Oncol. 2016; 5:713-20.
    
74. Brathwaite S, Yearsley MM, Bekaii-Saab T, Wei L, Schmidt CR, Dillhoff ME, Frankel WL, Hays JL, Wu C, Abdel-Misih S. Appendiceal Mixed Adeno-Neuroendocrine Carcinoma: A Population-Based Study of the Surveillance, Epidemiology, and End Results Registry. Front Oncol. 2016; 6:148 Epub 2016 June 13
    View PubMed
75. Mikhail S, Ciombor K, Noonan A, Wu C, Goldberg R, Zhao W, Wei L, Mathey K, Yereb M, Timmers C, Bekaii-Saab T. Upfront molecular testing in patients with advanced gastro-esophageal cancer: Is it time yet? Oncotarget. 2015 Sep 8; 6: (26)22206-13.
    View PubMed
76. Wu C, Mikhail S, Wei L, Timmers C, Tahiri S, Neal A, Walker J, El-Dika S, Blazer M, Rock J, Clark DJ, Yang X, Chen JL, Liu J, Knopp MV, Bekaii-Saab T. A phase II and pharmacodynamic study of sunitinib in relapsed/refractory oesophageal and gastro-oesophageal cancers. Br J Cancer. 2015 Jul 14; 113 (2):220-5 Epub 2015 July 07
    View PubMed
77. Petullo B, Wei L, Yereb M, Neal A, Rose J, Bekaii-Saab T, Wu C. A phase II study of biweekly pralatrexate and docetaxel in patients with advanced esophageal and gastroesophageal carcinoma that have failed first-line platinum-based therapy. J Gastrointest Oncol. 2015 Jun; 6(3):336-40.
    View PubMed
78. Blazer M, Wu C, Goldberg RM, Phillips G, Schmidt C, Muscarella P, Wuthrick E, Williams TM, Reardon J, Ellison EC, Bloomston M, Bekaii-Saab T. Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas. Ann Surg Oncol. 2015 Apr; 22(4):1153-9. Epub 2014 Oct 31.
    View PubMed
79. Ciombor KK, Wu C, Goldberg RM. Recent Therapeutic Advances in the Treatment of Colorectal Cancer. Annu Rev Med. 2015; 14(66):83-95.
    
80. Nichols SD, Albert S, Shirley L, Schmidt C, Abdel-Misih S, El-Dika S, Groce JR, Wu C, Goldberg RM, Bekaii-Saab T, Bloomston M. Outcomes in patients with obstructive jaundice from metastatic colorectal cancer and implications for management. J Gastrointest Surg. 2014 Dec; 18(12):2186-91. Epub 2014 Oct 10.
    View PubMed
81. Haraldsdottir S, Hampel H, Wei L, Wu C, Frankel W, Bekaii-Saab T, de la Chapelle A, Goldberg RM. Prostate cancer incidence in males with Lynch syndrome. Genet Med. 2014 Jul; 16(7):553-7. Epub 2014 Jan 16.
    View PubMed
82. Bekaii-Saab T, Wu C. Seeing the forest through the trees: a systematic review of the safety and efficacy of combination chemotherapies used in the treatment of metastatic colorectal cancer. Crit Rev Oncol Hematol. 2014 Jul; 91: (1)9-34.
    View PubMed
83. Weinberg BA, Wang H, Yang X, Wu CS, Pishvaian MJ, He AR, Marshall JL, Hwang JJ. Maintenance therapy with capecitabine in patients with resected pancreatic adenocarcinoma after adjuvant therapy: a retrospective cohort study. Gastrointest Cancer Res. 2014 May; 7 (3-4):91-7
    View PubMed
84. Wu C, Fernandez SA, Criswell T, Chidiac TA, Guttridge D, Villalona-Calero M, Bekaii-Saab TS. Disrupting cytokine signaling in pancreatic cancer: a phase I/II study of etanercept in combination with gemcitabine in patients with advanced disease. Pancreas. 2013 Jul; 42(5):813-8.
    View PubMed
85. Haraldsdottir S, Wu C, Bloomston M, Goldberg RM. What is the optimal neo-adjuvant treatment for liver metastasis? Ther Adv Med Oncol. 2013 Jul; 5 (4):221-34
    View PubMed
86. Olson EM, Abdel-Rasoul M, Maly J, Wu CS, Lin NU, Shapiro CL. Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab. Ann Oncol. 2013 Jun; 24 (6):1526-33 Epub 2013 Mar 04
    View PubMed
87. Wu C, Goldberg RM. Colon Cancer: Revisiting landmark trials and identifying new therapies. Nature Reviews Clinical Oncology. 2013; 10:71-2.
    
88. Wu C, Goldberg RM. New Drugs in the Frontier of Treatment of Metastatic Colorectal Cancer. Current Colorectal Cancer Reports. 2012 May.
    
89. Wu C, Bekaii-Saab T. CpG Island Methylation, Microsatellite Instability, and BRAF Mutations and Their Clinical Application in the Treatment of Colon Cancer. Chemother Res Pract. 2012; 2012: 359041.
    View PubMed
90. Haraldsdottir S, Rose J, Wu C, Wei L, Goldberg RM, Bekaii-Saab T. A Single Institutional Experience with Panitumumab in Metastatic Colorectal Cancer. Journal of Cancer Therapy. 2012; 3:948-55.
    
91. Wu C, Hwang J. Treatment of Metastatic Colorectal Cancer in the Elderly. Annals of Gastroenterology & Hepatology. 2012; 3(1):81-7.
    
92. Murray J, Wu C, Weiner LM. Why Cetuximab is Not Active in the Adjuvant Setting. Current Colorectal Cancer Reports. 2011; 7(3):211-7.
    
93. Wu C, Charabaty A, Pishvaian MJ, Marshall JL. Molecularly Targeted Therapy for Metastatic Colon Cancer: Proven Treatments and Promising New Agents. Current Colorectal Cancer Reports. 2010; 6:193-8.
    
94. Park HY, Wu C, Yaar M, Stachur CM, Kosmadaki M, Gilchrest BA. Role of BMP-4 and Its Signaling Pathways in Cultured Human Melanocytes. Int J Cell Biol. 2009; 2009:750482 Epub 2009 Dec 30
    View PubMed
95. Yaar M, Wu C, Park HY, Panova I, Schutz G, Gilchrest BA. Bone morphogenetic protein-4, a novel modulator of melanogenesis. J Biol Chem. 2006 Sep 1; 281 (35):25307-14 Epub 2006 July 11
    View PubMed
96. Park HY, Wu C, Yonemoto L, Murphy-Smith M, Wu H, Stachur CM, Gilchrest BA. MITF mediates cAMP-induced protein kinase C-beta expression in human melanocytes. Biochem J. 2006 May 1; 395 (3):571-8
    View PubMed
97. Wu C, Langan S, Kilmurray M, Lawlor D, Watson R. Efficacy of pulsed-dye laser for viral warts--an internal audit. Ir Med J. 2003 Mar; 96 (3):80, 82-3
    View PubMed